Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome

Heart

Volumn 97, Issue 13, 2011, Pages 1061-1066

  Oemrawsingh, R M ^a,b   Lenderink, T ^c   Akkerhuis, K M ^a   Heeschen, C ^d   Baldus, S ^e   Fichtlscherer, S ^f   Hamm, C W ^g   Simoons, M L ^a   Boersma, Eric ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UNIVERSITY OF HAMBURG   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 10; MYELOPEROXIDASE; PLACEBO; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; EPIDEMIOLOGIC METHODS; EUROPE; FEMALE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEROXIDASE; PREGNANCY PROTEINS; PROGNOSIS; TROPONIN T;

EID: 79958075780     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.197392     Document Type: Article

References (25)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43. (Pubitemid 34212626)
2. Baldus S, Heeschen C, Meinertz T, et al; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
3. Ridker PM, Danielson E, Fonseca FA, et al; the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
4. Brennan M, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. (Pubitemid 37288567)
5. Heeschen C, Dimmeler S, Hamm CW, et al; CAPTURE Study Investigators. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005;45:229-37. (Pubitemid 40094730)
6. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
7. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
8. Heeschen C, Dimmeler S, Fichtlscherer S, et al; CAPTURE Investigators. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291:435-41.
9. Heeschen C, Dimmeler S, Hamm CW, et al; CAPTURE Study Investigators. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003;107:2109-14.
10. Prasad KS, Andre P, Yan Y, et al. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003;10:356-61. (Pubitemid 36936607)
11. Heeschen C, Dimmeler S, Hamm CW, et al; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11. (Pubitemid 36337321)
12. Westerhout CM, Fu Y, Lauer MS, et al; GUSTO-IV ACS Trial Investigators. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol 2006;48:939-47. (Pubitemid 44292443)
13. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72.
14. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3.
15. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-9. (Pubitemid 29249431)
16. Vita JA, Brennan M, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004;110:1134-9. (Pubitemid 39319014)
17. McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 2005;111:2798-804. (Pubitemid 40791552)
18. Khurana R, Moons L, Shafi S, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005;111:2828-36. (Pubitemid 40791556)
19. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci 2002;979:80-93. (Pubitemid 36121141)
20. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
21. Bassand JP, Hamm CW, Ardissino D, et al; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
22. Schieffer B, Drexler H. Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. Am J Cardiol 2003;91:12H-18H.
23. Ridker PM, Cannon CP, Morrow D, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
24. Kennon S, Price CP, Mills PG, et al. Cumulative risk assessment in unstable angina: clinical, electrocardiographic, autonomic, and biochemical markers. Heart 2003;89:36-41. (Pubitemid 36044286)
25. Herren KR, Mackway-Jones K, Richards CR, et al. Is it possible to exclude a diagnosis of myocardial damage within six hours of admission to an emergency department? Diagnostic cohort study. BMJ 2001;323:372.